ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

An EMR-based prompt significantly boosted molecular testing rates and detection of actionable mutations in early-stage, ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Thanks to federally funded cancer research and clinical trials at Johns Hopkins, John Ryan has been able to attend ...

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic to identify individuals with non–small cell lung cancer (NSCLC) and high c-Met protein overexpression who may be ...

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...